• 2561 Citations
1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

One focus of my research is to test whether our chimeric suicide gene (CD34-TK) can be used to separate the life-threatening development of graft-versus-host disease from the beneficial graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation. The CD34-TK gene consists of a HSV thymidine kinase fused to the extracellular and transmembrane domains of CD34. A second focus of my research is to characterize the quantity, phenotype and function of human T lymphocytes, CD34+ hematopoietic stem cells (HSCs) and acute myeloid leukemia stem cells (LSCs) in the peripheral blood before and after treatment of normal donors or leukemic patients with granulocyte colony stimulating factor (G-CSF) or the CXCR4 antagonist, AMD3100. Egress (mobilization) of HSCs and LSCs from the bone marrow to the peripheral blood can be induced by cytokines like G-CSF or by small molecule inhibitors of CXCR4 like AMD3100. AMD3100 is the most promising mobilizing agent currently in clinical development.

Fingerprint Dive into the research topics where Michael Rettig is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

Vadakekolathu, J., Minden, M. D., Hood, T., Church, S. E., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E. J., Patel, T., Ibrahimova, N., Warren, S. E., Arruda, A., Liang, Y., Smith, T. H., Foulds, G. A., Bailey, M. D., Gowen-MacDonald, J., Muth, J., Schmitz, M., Cesano, A. & 9 others, Pockley, A. G., Valk, P. J. M., Löwenberg, B., Bornhäuser, M., Tasian, S. K., Rettig, M. P., Davidson-Moncada, J. K., Dipersio, J. & Rutella, S., Jun 3 2020, In : Science translational medicine. 12, 546, eaaz0463.

Research output: Contribution to journalArticle

  • 2 Scopus citations

    Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient

    Oza, A., Rettig, M. P., Powell, P., O'Brien, K., Clifford, D. B., Ritchey, J., Gehrs, L., Hollaway, J., Major, E., Fehniger, T. A., Miller, C. A., Soon-Shiong, P., Rock, A. & DiPersio, J. F., Jun 9 2020, In : Blood Advances. 4, 11, p. 2387-2391 5 p.

    Research output: Contribution to journalArticle

    Open Access
    1 Scopus citations
    Open Access
    1 Scopus citations

    Targeting CXCR4 in AML and ALL

    Cancilla, D., Rettig, M. P. & DiPersio, J. F., Sep 4 2020, In : Frontiers in Oncology. 10, 1672.

    Research output: Contribution to journalReview article

    Open Access
  • 68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity

    Sivapackiam, J., Kabra, S., Speidel, S., Sharma, M., Laforest, R., Salter, A., Rettig, M. P. & Sharma, V., May 2019, In : PloS one. 14, 5, e0215579.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations